Cyprus imposes €100 per day limit on ATM withdrawals. Until now, depositors were able to withdraw up to €260 per day at Cyprus Popular Bank. Restriction will remain in place until further notice. [View news story]
Get ready for S&P 1500 from the euphoria related to 24th hour cyprus bailout deal
Crisis on. S&P 500 futures -1% and the euro -1.2% as Brussels "faced with a drowning member state, instead of throwing the Cypriot people a lifebuoy, (throws) a millstone around its neck." EU leaders risk triggering bank runs in Cyprus (and elsewhere?) by going after bank depositors to fund the country's bank bailout. [View news story]
Expect futures to be green by morning once some EU official says that a better deal has been reached, 3. 30 ramp will be the cherry on top
It is not only Zytiga and Xtandi, there is a TAK 300 compound by Takeda in the pipeline and a bunch of other compounds.
When you treat mostly 70+ yr old patients, it is easy to prescribe another antiandrogen pill rather than referring them for Provenge.
With Zytiga, the PSA starts dropping instantly and you know it is working while with Provenge, you dont even know whether it is working or not. There is some buzz in the oncology community as to the ' alternate explanation' for survival benefit with Provenge. http://bit.ly/X8Knlq
Provenge is not going to catch on. I can see Zytiga, Xtandi combination given pre-chemo with tremendous response, may be even pre-surgery or radiation in another 3-4 years.
S&P futures tumble, -0.6% following the weak China PMI print. The euro extends its bear run, -0.3% to $1.2330. Hardest hit are the aussie, -0.7% to $0.9668, and Australian shares, -1%. [View news story]
Asian markets are cheering the bad numbers after initial drop...QE hopium more addictive than bath salts
Revisiting The U.K., QE3, And The Spring Switch [View article]
Correct me if I am getting it wrong... No QE- 'spring switch' -> bullish for equities QE- Bullish by common sense.... So in your opinion, there can be no downside..Market will keep going up?
Europe May Fail Due To Sovereignty Issues [View article]
All the doom and gloom make perfect sense,but I will not invest based on this..not yet. The central banks/politicians can prop up this charade for many more months .There is so much money on the sidelines that folks want to invest in equities and the fund managers are waiting for any excuse to run up the bull market until everything falls of the cliff.
6 Companies That Could Revolutionize Medicine -- And Portfolios [View article]
Few things about NeuVax... Basically there are 3 challenges. 1. Nuances about the Her 2 testing 2. Crowded field of alternate drugs 3. Herceptin ( patent expiry in 2019)and the already available drugs are so expensive .
1. Standard practice to assess Her 2 Neu expression is slightly controversial and ASCO has come up with guidelines...
Routinely, Her2 Immunostaining is done first for screening on all breast cancer patients. If it stains 3+ , it is considered Her2 positive. If 1+, it is considered negative.
If 2+, further testing using FISH probes are done which gives a cut off number to see whether it is positive or not.
All together only around 20% of breast cancer ends up being Her2 + and receive herceptin.
Given the huge expense, I doubt whether herceptin will be approved in 1+ IHC patients, let alone combining it with a new vaccine. That leaves only the 3+ and 2+ staining group( 2+ needs to be confirmed with FISH testing first ) .
The phase II poster is unclear about the percentage breakdown of the patients with 1+ ,2+ or 3+ staining !!!
Also there are another 4-5 drugs like pertuzumab, lapatanib, TDM etc which have already proven efficacy in Her 2+ cancer and they are routinely combined with Herceptin now in the metastatic cancer.
Any phase III study needs a high threshold for approval to be cost effective. Globally , countries are finding it hard even to afford herceptin( cost more than 50,000 $ per year) , so the chances of a sophisticated vaccine catching on is questionable.
Barrick Gold: Strong Signs Of A Capitulation Buying Opportunity [View article]
Cyprus imposes €100 per day limit on ATM withdrawals. Until now, depositors were able to withdraw up to €260 per day at Cyprus Popular Bank. Restriction will remain in place until further notice.
[View news story]
Crisis on. S&P 500 futures -1% and the euro -1.2% as Brussels "faced with a drowning member state, instead of throwing the Cypriot people a lifebuoy, (throws) a millstone around its neck." EU leaders risk triggering bank runs in Cyprus (and elsewhere?) by going after bank depositors to fund the country's bank bailout. [View news story]
Dendreon Dodges A Bullet [View article]
When you treat mostly 70+ yr old patients, it is easy to prescribe another antiandrogen pill rather than referring them for Provenge.
With Zytiga, the PSA starts dropping instantly and you know it is working while with Provenge, you dont even know whether it is working or not. There is some buzz in the oncology community as to the ' alternate explanation' for survival benefit with Provenge.
http://bit.ly/X8Knlq
Dendreon Dodges A Bullet [View article]
New Drug Could Be Game Changer For Sanofi [View article]
S&P futures tumble, -0.6% following the weak China PMI print. The euro extends its bear run, -0.3% to $1.2330. Hardest hit are the aussie, -0.7% to $0.9668, and Australian shares, -1%. [View news story]
Canadian Oil & Gas Equities May Have Finally Bottomed Out [View article]
Making A Case For InterDigital [View article]
Revisiting The U.K., QE3, And The Spring Switch [View article]
Correct me if I am getting it wrong...
No QE- 'spring switch' -> bullish for equities
QE- Bullish by common sense....
So in your opinion, there can be no downside..Market will keep going up?
Spain - The Next Domino Is Getting Ready To Tumble [View article]
Heckmann Q4 And 2011 Year-End Earnings Report; More Than Meets The Eye [View article]
Europe May Fail Due To Sovereignty Issues [View article]
6 Companies That Could Revolutionize Medicine -- And Portfolios [View article]
Basically there are 3 challenges.
1. Nuances about the Her 2 testing
2. Crowded field of alternate drugs
3. Herceptin ( patent expiry in 2019)and the already available drugs are so expensive .
1. Standard practice to assess Her 2 Neu expression is slightly controversial and ASCO has come up with guidelines...
Routinely, Her2 Immunostaining is done first for screening on all breast cancer patients. If it stains 3+ , it is considered Her2 positive. If 1+, it is considered negative.
If 2+, further testing using FISH probes are done which gives a cut off number to see whether it is positive or not.
All together only around 20% of breast cancer ends up being Her2 + and receive herceptin.
Given the huge expense, I doubt whether herceptin will be approved in 1+ IHC patients, let alone combining it with a new vaccine. That leaves only the 3+ and 2+ staining group( 2+ needs to be confirmed with FISH testing first ) .
The phase II poster is unclear about the percentage breakdown of the patients with 1+ ,2+ or 3+ staining !!!
Also there are another 4-5 drugs like pertuzumab, lapatanib, TDM etc which have already proven efficacy in Her 2+ cancer and they are routinely combined with Herceptin now in the metastatic cancer.
Any phase III study needs a high threshold for approval to be cost effective. Globally , countries are finding it hard even to afford herceptin( cost more than 50,000 $ per year) , so the chances of a sophisticated vaccine catching on is questionable.